GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAP-SVD)
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Cerebral small vessel disease (cSVD), a result of neurovascular cell dysfunction, is a major
cause of stroke, dementia and mobility problems worldwide. Vascular risk factor control alone
may not be sufficient to prevent the development of vascular cognitive impairment (VCI) in
patients with cSVD according to previous clinical trials.
The presence of glucagon-like peptide-1 receptor (GLP-1R) in cerebral microglia may reveal a
potential therapeutic target for prevention of cSVD progression and its disabling clinical
outcomes. At the cellular and animal experimentation levels, GLP-1R agonist demonstrated
reversal of some pathogenic processes in cSVD. However, its application to cSVD patients
remains to be elucidated.
Investigator aims to investigate the safety and efficacy of GLP-1R agonist in patients with
moderate-to-severe cSVD.